Le Pen C - Search Results

1

Hospital reimbursement price cap for cancer drugs: the French experience in controlling hospital drug expenditures.

Degrassat-Théas A, Bensadon M, Rieu C, Angalakuditi M, Le Pen C, Paubel P. Degrassat-Théas A, et al. Among authors: le pen c. Pharmacoeconomics. 2012 Jul 1;30(7):565-73. doi: 10.2165/11588320-000000000-00000. Pharmacoeconomics. 2012. PMID: 22686661

2

Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?

Degrassat-Théas A, Paubel P, Parent de Curzon O, Le Pen C, Sinègre M. Degrassat-Théas A, et al. Among authors: le pen c. Pharmacoeconomics. 2013 Apr;31(4):335-43. doi: 10.1007/s40273-013-0039-4. Pharmacoeconomics. 2013. PMID: 23529210

3

Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.

Bocquet F, Paubel P, Fusier I, Cordonnier AL, Sinègre M, Le Pen C. Bocquet F, et al. Among authors: le pen c. Appl Health Econ Health Policy. 2015 Feb;13(1):47-59. doi: 10.1007/s40258-014-0125-6. Appl Health Econ Health Policy. 2015. PMID: 25189295

4

Drug pricing and reimbursement in France. Towards a new model?

Le Pen C. Le Pen C. Pharmacoeconomics. 1996;10 Suppl 2:26-36. doi: 10.2165/00019053-199600102-00006. Pharmacoeconomics. 1996. PMID: 10163433 Review.

5

Biosimilar granulocyte colony-stimulating factor uptakes in the EU-5 markets: a descriptive analysis.

Bocquet F, Paubel P, Fusier I, Cordonnier AL, Le Pen C, Sinègre M. Bocquet F, et al. Among authors: le pen c. Appl Health Econ Health Policy. 2014 Jun;12(3):315-26. doi: 10.1007/s40258-014-0087-8. Appl Health Econ Health Policy. 2014. PMID: 24578185

6

Diagnosis related group costs in a regulated environment. A note about their economic interpretation.

Le Pen C, Berdeaux G. Le Pen C, et al. Pharmacoeconomics. 2000 Feb;17(2):115-20. doi: 10.2165/00019053-200017020-00001. Pharmacoeconomics. 2000. PMID: 10947335

7

The drug budget silo mentality: the French case.

Le Pen C. Le Pen C. Value Health. 2003 Jul-Aug;6 Suppl 1:S10-9. doi: 10.1046/j.1524-4733.6.s1.2.x. Value Health. 2003. PMID: 12846922 Free article.

8

Cost of illness and disease severity in a cohort of French patients with Parkinson's disease.

LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziégler M. LePen C, et al. Pharmacoeconomics. 1999 Jul;16(1):59-69. doi: 10.2165/00019053-199916010-00006. Pharmacoeconomics. 1999. PMID: 10539122 Clinical Trial.

9

The burden of age-related macular degeneration: results of a cohort study in two French referral centres.

Bonastre J, Le Pen C, Soubrane G, Quentel G. Bonastre J, et al. Among authors: le pen c. Pharmacoeconomics. 2003;21(3):181-90. doi: 10.2165/00019053-200321030-00003. Pharmacoeconomics. 2003. PMID: 12558468

10

The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction.

LePen C, Lilliu H, Keller T, Fiessinger S. LePen C, et al. Pharmacoeconomics. 1998 Jul;14(1):49-58. doi: 10.2165/00019053-199814010-00005. Pharmacoeconomics. 1998. PMID: 10182194 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75 results

Search Page

Filters